Heart Failure with Preserved Ejection Fraction and Sudden Death: How to Identify High Risk Patients?
Background: Cardiac failure with preserved ejection fraction corresponds to half of the cardiac failure cases, having a similar prognosis to patients with reduced ejection fraction. Cardiac sudden death is responsible to about one quarter of the death on these patients. Despite some trials were intended to identify patients with a higher risk to these outcome, it is not already know: how we should proceed to stratify the risk of sudden death in this patients. Methods: To assess the profile of patients with cardiac sudden death and cardiac failure with preserved ejection fraction, we did a literature review, searching for the newer articles about the theme. Outcome: Several trials were published involving patients with divers characteristics that can help us to identify patients with a higher risk of sudden death. The publication of risk score demonstrated that would be possible to identify patients with a >10% risk of sudden death in 5 years, what would be equivalent to the risk of reduced ejection fraction patients eligible to implantable cardioverter-defibrillator (ICD) therapy. Trials with electrophysiological study and programmed ventricular stimulation showed a good strategy to identify low risk patients for future arrhythmic events. Conclusion: Sudden death must be a target of the therapy in the patients with preserved heart failure. Efforts should be done with the objective to identify higher risk patients and search for the better risk stratification strategy, and after that, the definition of the benefit or not, of the invasive therapy as ICD.
Keywords: Sudden Death; Cardiac Faillure; Preserved Ejection Fraction;
– Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al. ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC), 2015. European Heart Journal (2016) 37, 2129–2200 doi:10.1093/eurheartj/ehw128.
- Curtis LH, Whellan DJ, Hammill BG, Hernandez AF, Anstrom KJ, Shea AM, Schulman KA. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med. 2008;168:418–424. doi: 10.1001/archinternmed.2007.80
- Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZEHF Investigators and Coordinators. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347–356. doi: 10.1016/j.jacc.2008.04.028.
- Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study).
Am J Cardiol. 2008;101:1016–1022. doi: 10.1016/j.amjcard.2007.11.061.
- Vaduganathan M, Michel A, Hall K, et al. Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. Eur J Heart Fail 2016;18:54–65.
- Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251e9.
- Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. JAMA 2006;296:2209e16.
- Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012;33:1750e7.
- Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–92.
- Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and Norbidity (CHARM) program. Circulation 2004;110:
- Zile MR, Gaasch WH, Anand IS, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) trial. Circulation 2010;121:1393–405.
- Adabag S, Smith LG, Anand IS, Berger AK, Luepker RV (2012) Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail 18(10):749–754. doi:10.1016/j. cardfail.2012.08.357.
- Hamaguchi S, Kinugawa S, Sobirin MA, Goto D, Tsuchihashi- Makaya M, Yamada S, Yokoshiki H, Tsutsui H, Investigators J-C (2012) Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. Circ J 76(7):1662–1669.
- Muthiah Vaduganathan, MD, MPH,a Brian L. Claggett, PHD,a Neal A. Chatterjee, MD, MSC,b Inder S. Anand, MD, PHD,c Nancy K. Sweitzer, MD, PHD,d James C. Fang, MD,e Eileen O’Meara, MD,f Sanjiv J. Shah, MD,g Sheila M. Hegde, MD, MPH,a Akshay S. Desai, MD, MPH,a Eldrin F. Lewis, MD, MPH,a Jean Rouleau, MD,f Bertram Pitt, MD,h Marc A. Pfeffer, MD, PHD,a Scott D. Solomon, MD (2018).
- Michael R. Zile, MD; William H. Gaasch, MD; Inder S. Anand, MD, DPhil (Oxon);
Markus Haass, MD; Peter E. Carson, MD et al. for the I-Preserve Investigators (2010) - Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial.
- Selcuk Adabag1,2, Thomas S. Rector1,2, Inder S. Anand1,2*, John J. McMurray3,Michael Zile4, Michel Komajda5, Robert S. McKelvie6, Barry Massie7, and Peter E. Carson8. 2014 - A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction.
- SCD-HEFT Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F,
Boehmer JP, Carlson MD, Frantz RP, McNulty SE, Rogers JG, Anderson J, Johnson
GW, Walsh MN, Poole JE, Mark DB, Lee KL, Bardy GH. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 009;120:2170–2176.
- Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter
defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-37.
- Adabag S, Patton KK, Buxton AE, et al. Association of Implantable Cardioverter
Defibrillators With Survival in Patients With and Without Improved Ejection Fraction:
Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial. JAMA Cardiol
- Sudden Cardiac Death Risk Prediction in Heart Failure with Preserved Ejection
Fraction Selcuk Adabag, MD, MS, FHRS, Lisa Langsetmo, PhD 2019 - Heart Rhythm (2020), doi: https://doi.org/10.1016/j.hrthm.2019.12.009.
- Selcuk Adabag, MD, MS; Kristen K. Patton, MD; Alfred E. Buxton, MD; Thomas S. Rector, PhD, PharmD; Kristine E. Ensrud, MD et al. 2017 - Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.
- Stecker EC, Vickers C,Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J AmColl Cardiol. 2006; 47(6):1161-1166.
- Singh SN, Fisher SG, Carson PE, et al. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators. J Am Coll Cardiol. 1998;32:942–7.
- Teerlink JR, Jalaluddin M, Anderson S, Kukin ML, Eichhorn EJ, Francis G, et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation. 2000;101:40–6.
- Doval HC, Nul DR, Grancelli HO, Varini SD, Soifer S, Corrado G, et al. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA investigators. Circulation. 1996;94:3198–203
- Clementy N, Bisson A, Challal F, Andre C, Pierre B, Fauchier L, et al. Nonsustained ventricular tachycardia at the time of implantation predicts appropriate therapies on rapid ventricular arrhythmia in primary prevention patients with nonischemic cardiomyopathy: Results From the Very-High-Rate Registry. JACC Clin Electrophysiol. 2017;3:1338–9.
- You Zhou1 & Shuang Zhao1 & Keping Chen1 & Wei Hua1 & Yangang Su2 & Silin Chen3 & Zhaoguang Liang4 & Wei Xu5 & Shu Zhang1. 2019 - Predictive value of rapid-rate non-sustained ventricular tachycardia in the occurrence of appropriate implantable cardioverter-defibrillator therapy. Journal of Interventional Cardiac Electrophysiology https://doi.org/10.1007/s10840-019-00557-4.
- Abadag, S, Cogsweel R, Akdemir B, Alexy T, Ash J, Gutierrez A. 2019 – Heart Faillure with preserved ejection fraction is a highly arrythmogenic disease – Circulation, 140:A11898.
- Konstantinos A. Gatzoulis , Dimitrios Tsiachris1, Petros Arsenos1,
Christos-Konstantinos Antoniou 1, Polychronis Dilaveris 1, Skevos et al – 2018 - Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study.
- Gabriela Hilfiker, Andreas W Schoenenberger, Paul Erne, Richard Kobza – 2015 - Utility of electrophysiological studies to predict arrhythmic events. World J Cardiol 2015 June 26; 7(6): 344-350 ISSN 1949-8462 (online).
Copyright (c) 2020 Bruno Finkler, Tiago Luiz Luz Leiria, Clovis Fröemming Jr, Javier Pinos, Danilo Barros Zanotta, Marcelo Lapa Kruse, Leonardo Martins Pires, Gustavo Glotz de Lima
This work is licensed under a Creative Commons Attribution 4.0 International License.